A closer look at “ASCO Spotlight: New Lung Cancer Drug Ivonescimab Prompts Global Call for Inclusive Clinica”, exactly as the source publishes it. At the recent American Society of Clinical Oncology (ASCO) meeting, the emergence of ivonescimab—a novel bispecific antibody for non-small cell lung cancer At the recent American Society of Clinical Oncology (ASCO) meeting, the emergence of ivonescimab—a novel bispecific antibody for non-small cell lung cancer—captured the medical community's attention. Developed by Akeso and Summit Therapeutics in China, the drug utilizes a dual-action mechanism to target both PD-1 and VEGF pathways, showing promising results in progression-free survival for advanced lung cancer patients.
However, the clinical enthusiasm is tempered by a significant geographic caveat: the current data is derived from a predominantly East Asian population. Leading oncologists are now calling for expansive, multi-center trials to test the drug’s safety and efficacy in more diverse, global cohorts. This listing links straight to the original page, where the content is available in full.